Tag
This article reviews a 13-year longitudinal study assessing blood-based biomarkers’ effectiveness in predicting all-cause dementia among community-dwelling older adults, highlighting their modest sensitivity and enhanced predictive value wh
Plasma phosphorylated tau biomarkers overlap in Alzheimer’s and prion diseases, risking diagnostic confusion. The NfL/p-tau217 ratio emerges as an accurate plasma biomarker to distinguish prion diseases from Alzheimer’s, improving diagnosti
This study reveals that even amateur soccer heading causes immediate, transient increases in blood biomarkers p-tau217 and S100B, indicating acute neural impact and suggesting a dose-response effect.
Plasma %p-tau217 plus eMTBR-tau243 showed strong agreement with amyloid/tau PET staging, tracked clinical severity, and aligned with neuropathology, supporting a scalable blood-based approach to Alzheimer disease biological staging.
In the HUNT Study, higher midlife waist-to-height ratio and BMI predicted higher late-life plasma p-tau217 and biomarker-verified Alzheimer dementia, whereas higher adiposity in late life was associated with lower biomarker levels and lower
Women with high amyloid-β show higher p-tau217 levels and faster tau accumulation than men, leading to greater cognitive decline. This sex-specific tau response may redefine preclinical Alzheimer’s diagnostics and therapeutics.
This review synthesizes recent clinical evidence on the integration of plasma p-tau217 and eMTBR-tau243, highlighting how sequential biomarker testing improves the diagnosis of symptomatic Alzheimer’s disease and predicts longitudinal cogni
This review synthesizes evidence on the impact of kidney function, BMI, and anemia on plasma p-tau217 diagnostic accuracy, advocating for subgroup-specific cutoff strategies to improve clinical outcomes.
A multi-cohort study demonstrates that women with amyloid-β pathology show higher plasma p-tau217 levels and faster tau PET accumulation than men, providing a biological basis for their increased risk of rapid cognitive decline in preclinic
Standard single cutoffs for plasma p-tau217 are significantly confounded by kidney function, BMI, and anemia. A new study demonstrates that subgroup-specific or double-cutoff strategies markedly improve diagnostic accuracy and cost-effectiv
This review synthesizes recent high-impact evidence on plasma p-tau217, demonstrating its superior utility in identifying amyloid pathology, predicting cognitive decline, and optimizing recruitment for primary prevention trials in cognitive
A pivotal longitudinal study demonstrates that plasma p-tau217 and GFAP accurately predict amyloid-β and tau deposition, cognitive decline, and dementia risk in adults with Down syndrome, offering a transformative, non-invasive tool for cli
Obicetrapib, a CETP inhibitor, lowers Alzheimer’s biomarkers like p-tau217 in ASCVD patients, especially ApoE4 carriers, suggesting a potential preventive strategy for high-risk individuals.
Pregnancy hypertension is independently associated with higher serum p-tau217 levels in midlife women, suggesting a link to preclinical Alzheimer’s disease pathology and potential for early screening and intervention.
